Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment.

Pakpour S, Bhanvadia A, Zhu R, Amarnani A, Gibbons SM, Gurry T, Alm EJ, Martello LA.

Microbiome. 2017 Nov 13;5(1):148. doi: 10.1186/s40168-017-0368-1.

2.

Clostridium difficile infection in the elderly: an update on management.

Asempa TE, Nicolau DP.

Clin Interv Aging. 2017 Oct 24;12:1799-1809. doi: 10.2147/CIA.S149089. eCollection 2017. Review.

3.

Prevalence of binary toxin positive Clostridium difficile in diarrhoeal humans in the absence of epidemic ribotype 027.

McGovern AM, Androga GO, Knight DR, Watson MW, Elliott B, Foster NF, Chang BJ, Riley TV.

PLoS One. 2017 Nov 8;12(11):e0187658. doi: 10.1371/journal.pone.0187658. eCollection 2017.

4.

Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis.

Eze P, Balsells E, Kyaw MH, Nair H.

J Glob Health. 2017 Jun;7(1):010417. doi: 10.7189/jogh.07.010417.

5.

Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China.

Li C, Duan J, Liu S, Meng X, Fu C, Zeng C, Wu A.

Infection. 2017 Oct;45(5):621-628. doi: 10.1007/s15010-017-1024-1. Epub 2017 May 11.

6.

Human Clostridium difficile infection caused by a livestock-associated PCR ribotype 237 strain in Western Australia.

Mc Govern AM, Foster NF, Pereira LA, Knight DR, Elliott B, Chang BJ, Riley TV.

JMM Case Rep. 2016 Aug 30;3(4):e005062. doi: 10.1099/jmmcr.0.005062. eCollection 2016 Aug.

7.

Risk factors for Clostridium difficile infection in HIV-infected patients.

Imlay H, Kaul D, Rao K.

SAGE Open Med. 2016 Dec 14;4:2050312116684295. doi: 10.1177/2050312116684295. eCollection 2016.

8.

Conventional and alternative treatment approaches for Clostridium difficile infection.

Aljarallah KM.

Int J Health Sci (Qassim). 2017 Jan-Mar;11(1):1-10. Review.

9.

A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissions.

Nanwa N, Sander B, Krahn M, Daneman N, Lu H, Austin PC, Govindarajan A, Rosella LC, Cadarette SM, Kwong JC.

PLoS One. 2017 Mar 3;12(3):e0172410. doi: 10.1371/journal.pone.0172410. eCollection 2017.

10.

The Association between GABA-Modulators and Clostridium difficile Infection - A Matched Retrospective Case-Control Study.

Ström J, Tham J, Månsson F, Ahl J, Savidge TC, Dann SM, Resman F.

PLoS One. 2017 Jan 6;12(1):e0169386. doi: 10.1371/journal.pone.0169386. eCollection 2017.

11.

Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations.

Balsells E, Filipescu T, Kyaw MH, Wiuff C, Campbell H, Nair H.

J Glob Health. 2016 Dec;6(2):020410. doi: 10.7189/jogh.06.020410. Review.

12.

The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis.

Tang C, Cui L, Xu Y, Xie L, Sun P, Liu C, Xia W, Liu G.

Sci Rep. 2016 Nov 29;6:37865. doi: 10.1038/srep37865.

13.

Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.

Kuntz JL, Baker JM, Kipnis P, Li SX, Liu V, Xie Y, Marcella S, Escobar GJ.

Infect Control Hosp Epidemiol. 2017 Jan;38(1):45-52. doi: 10.1017/ice.2016.232. Epub 2016 Oct 20.

14.

Community- and Healthcare-Associated Clostridium difficile Infections, Finland, 2008-2013(1).

Kotila SM, Mentula S, Ollgren J, Virolainen-Julkunen A, Lyytikäinen O.

Emerg Infect Dis. 2016 Oct;22(10):1747-53. doi: 10.3201/eid2210.151492.

15.

Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.

Bloomfield LE, Riley TV.

Infect Dis Ther. 2016 Sep;5(3):231-51. doi: 10.1007/s40121-016-0117-y. Epub 2016 Jul 1. Review.

16.

Clostridium difficile Infections amongst Patients with Haematological Malignancies: A Data Linkage Study.

Selvey LA, Slimings C, Joske DJ, Riley TV.

PLoS One. 2016 Jun 17;11(6):e0157839. doi: 10.1371/journal.pone.0157839. eCollection 2016.

17.

Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.

Rao K, Santhosh K, Mogle JA, Higgins PD, Young VB.

Infect Dis (Lond). 2016 Sep;48(9):663-9. doi: 10.1080/23744235.2016.1186832. Epub 2016 May 20.

18.

Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection.

Seekatz AM, Rao K, Santhosh K, Young VB.

Genome Med. 2016 Apr 27;8(1):47. doi: 10.1186/s13073-016-0298-8.

19.

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases.

Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER.

BMC Infect Dis. 2016 Apr 22;16:177. doi: 10.1186/s12879-016-1501-7.

20.

Clostridium difficile infection: a review of current and emerging therapies.

Ofosu A.

Ann Gastroenterol. 2016 Apr-Jun;29(2):147-54. doi: 10.20524/aog.2016.0006. Review.

Supplemental Content

Support Center